# A case of irAE gastritis caused by cemiplimab administration

## TL;DR

A 75-year-old woman developed immune-related gastritis after receiving cemiplimab for cervical cancer, which was diagnosed and treated with prednisolone.

## Contribution

This case report documents a rare instance of cemiplimab-induced immune-related gastritis and highlights its diagnostic features.

## Key findings

- Endoscopic and histopathological features confirmed immune-related gastritis following cemiplimab treatment.
- Symptoms improved after initiating prednisolone therapy.
- The case is consistent with irAE gastritis caused by other immune checkpoint inhibitors.

## Abstract

While various immune-related adverse events (irAEs) have been associated with the use of immune checkpoint inhibitors (ICIs), gastritis as an irAE remains a rarely documented condition. We report a case of immune-related gastritis following cemiplimab administration, accompanied by a review of the relevant literature.

A 75-year-old woman, gravida 4, para 2, underwent six cycles of cemiplimab as second-line treatment for FIGO stage IIB squamous cell carcinoma of the cervix. Cemiplimab was discontinued 140 days after the initial dose due to the onset of anorexia, nausea, and vomiting. However, her symptoms did not improve during the subsequent follow-up. Upper gastrointestinal endoscopy revealed erythema and edematous changes of the mucosa, predominantly in the pyloric region, along with friable, easily bleeding mucosa and white exudate. Histopathological examination of the biopsied tissue showed dense intraepithelial infiltration of CD8-positive lymphocytes. These findings were consistent with irAE gastritis. As fasting alone failed to improve the symptoms, prednisolone (PSL) was initiated, resulting in amelioration of both symptoms and endoscopic findings.

Cemiplimab-induced immune-related gastritis can be diagnosed based on its characteristic endoscopic and histopathological features, similar to irAE gastritis caused by other immune checkpoint inhibitors.